Novavax tumbles 30% as demands for COVID-19 vaccine decline

According to reports, the demand for its vaccine is also waning in the United States, where it was authorised for use among adults last month and was expected to be preferred by the skeptics of messenger RNA-based shots from Moderna Inc and Pfizer Inc.

valneva, vaccine maker valneva, revenue, pharma news, health news,
Its COVID-19 product sales should reach between 30 million euros and 40 million euros in 2022. (File)

Shares of Novavax fell about 30 percent on Tuesday after it cut its annual revenue forecast by half over falling demand for its COVID-19 shot from low- and middle-income nations.

According to a report by news agency Reuters, demand for its vaccine is also waning in the United States, where it was authorised for use among adults last month and was expected to be preferred by the skeptics of messenger RNA-based shots from Moderna Inc and Pfizer Inc.

But only 7,381 Novavax vaccine doses have been administered so far in the country and Chief Executive Stanley Erck said that its late launch could have hampered demand.

ALSO READ | US regulators OK new COVID-19 shot option from Novavax

The company now expects 2022 revenue between $2 billion and $2.3 billion, compared with its prior forecast of $4 billion to $5 billion when it was hoping to benefit from the demand for its shots as part of the COVAX vaccine sharing program.

Novavax shares fell 29.6 percent to close down at $40.28 a share. “Timing continues to be our enemy,” Novavax Chief Business Officer John Trizzino said in an interview as quoted by Reuters.

He said the company does not expect to pick up a significant market share of booster shots this fall as other vaccine makers roll out new shots designed to target newer COVID-19 variants.

Still, he said that developing its own updated version of the vaccine will help as the company gears up to compete next year.

“All of the obstacles that have been in our way in 2022 will not be there in ’23,” he said. Analysts still expect the company to capture a small but meaningful share of a fast-developing market for COVID-19 re-vaccinations.

ALSO READ | Over 42 lakh deaths in India prevented by Covid vaccines in 2021: Lancet study

It could still be a viable COVID vaccine player in the future $5-10 billion market as it has shown a comparable or better clinical profile versus mRNA vaccines, Jefferies analyst Roger Song said in a note.

(With inputs from Reuters)

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.

Photos